Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment

NCT00428220 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00428220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00428220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Lead sponsor
Pfizer
Phase
Not applicable
Overall status
Completed
Start date
July 31, 2007
Completion date
September 30, 2014
Enrollment
223 (actual)
Sites
113

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, advanced gastric cancer, advanced/metastatic non-small cell lung cancer, gastrointestinal stromal tumor, hepatocellular carcinoma, metastatic breast cancer, metastatic castration resistant prostate cancer, metastatic renal cell cancer, non-small cell lung cancer, pancreatic islet cell carcinoma, pancreatic neuroendocrine tumor, thyroid cancer